# Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

> **NCT00851552** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** bortezomib
- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **GENETIC:** gene expression analysis
- **GENETIC:** polymerase chain reaction
- **GENETIC:** polymorphism analysis
- **GENETIC:** proteomic profiling
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00851552
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of sponsor support
- **Last updated:** 2014-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851552, "Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00851552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*